id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-310661-hrvuhkq9	Patell, Rushad	Incidence of thrombosis and hemorrhage in hospitalized cancer patients with COVID‐19	2020-07-21		.txt	text/plain	3381	198	42	OBJECTIVES: To evaluate cumulative incidences of thrombotic and hemorrhagic events in hospitalized COVID‐19 patients with and without active cancer at 28 days. Among 129 patients that received therapeutic anticoagulation during hospitalization in the non-cancer cohort COVID coagulopathy was the most common indication (n=99, 76.7%), followed by atrial fibrillation (n=24, 18.6%) and prior VTE (n=10, 7.8%). When analyzing key thrombotic events (lower extremity or upper extremity DVT, pulmonary embolism, or arterial events), the cumulative incidence of thrombosis at day 28 in the non-cancer cohort was 10.2% (95% CI, 5.7% to 16.2%) and in the cancer cohort was 14.2% (95% CI, 4.7% to 28.7%, Figure 1B ). [28] A study that included screening for asymptomatic deep vein thrombosis in hospitalized COVID patients, identified 2 occurrences of DVT among 16 cancer patients, which was similar to the incidence observed in the non-cancer cohort. In a retrospective cohort study of hospitalized patients with COVID-19 we observed high rates of thrombosis and bleeding among patients with or without active cancer.	./cache/cord-310661-hrvuhkq9.txt	./txt/cord-310661-hrvuhkq9.txt